CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

AKO-002

pharmaceutical compound

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionAug 29, 2026
Entity authorityQ132861294 ↗
Source-derived summary

AKO-002, or AKO002, is a combination of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocybin and an undisclosed "specific plant bioactive" which is under development for the treatment of Alzheimer's disease. While the "specific plant bioactive" in the combination and the action of this compound have not been disclosed, certain plant compounds, such as the β-carboline harmine in Banisteriopsis caapi, are reversible monoamine oxidase A (MAO-A) inhibitors and inhibit the metabolism of psychedelic tryptamines, in turn potentiating their effects. AKO-002 is being developed by Akome Biotech. As of March 2022, the drug is in the preclinical research stage of development.

See also

List of investigational hallucinogens and entactogens

References

External links

AKO002 for Alzheimer's - Akome Biotech Ltd.

Editorial summary

“AKO-002” enters the record as pharmaceutical compound. Crown Archives preserves that source wording while asking what AKO-002, pharmaceutical and compound can confirm, complicate or overturn.

Editorial reviewA concise reference frame for defining the subject, testing terminology and identifying the institution closest to the evidence. The current lead gives the account dated anchors—2022—that can be checked directly. The selected authority fields contribute no independent date. Its strongest next move is a source search built around AKO-002, pharmaceutical and compound.
Editorial analysis

Why this record matters

“AKO-002” is worth following because a concise public description often conceals a longer documentary argument. Here, AKO-002, pharmaceutical and compound provides the most credible route into that argument.

Evidence profile

Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Aug 29, 2026. The linked authority identifier is Q132861294. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2022.

Critical limits

A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “AKO-002”, its source revision and the description used here.
  2. Expand the search: follow AKO-002 primary sources, AKO-002 archive and AKO-002 research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “AKO-002”?
  2. Which institution is responsible for the underlying evidence?
  3. What terminology or title could unlock a more precise catalogue search?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “AKO-002” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.